医学
髓系白血病
耐火材料(行星科学)
肠炎
免疫系统
免疫学
内科学
生物
天体生物学
作者
Pan Luo,Huiying Qiu,Yixia Yang,Jiaqi Wu,Xianmin Song,Guorong Fan,Liu Gao-lin,Junwei Gao
出处
期刊:Anti-Cancer Drugs
[Ovid Technologies (Wolters Kluwer)]
日期:2023-04-14
卷期号:34 (7): 896-900
被引量:1
标识
DOI:10.1097/cad.0000000000001470
摘要
Gilteritinib is currently approved in China for relapsed/refractory FLT3-mutated acute myeloid leukemia, and it is very important to monitor and report its adverse drug reaction (ADR) after post-marketing. This case report describes a patient who was diagnosed with acute myeloid leukemia harboring FLT3 mutations and developed a severe suspected immune-related enteritis during treatment with gilteritinib for maintenance therapy following allo-hematopoietic stem cell transplantation. According to the Naranjo probability scale, gilteritinib was defined as a 'possible' cause of ADR. Another suspicious inducement, graft-versus-host disease, can not be eluted and might represent a limitation in this case. To the best of our knowledge, this is the first report on gilteritinib-induced severe enteritis and will help physicians to keep vigilant, and detect and deal with time for possible ADR.
科研通智能强力驱动
Strongly Powered by AbleSci AI